The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Oct. 03, 2023
Filed:
Nov. 02, 2020
Applicant:
Piramal Enterprises Limited, Mumbai, IN;
Inventors:
Rajiv Sharma, Fremont, CA (US);
Sanjay Kumar, Mumbai, IN;
Vishal Mahajan, Thane, IN;
Komal Bajaj, Mumbai, IN;
Pallavi Godse, Pune, IN;
Assignee:
PIRAMAL ENTERPRISES LIMITED, Mumbai, IN;
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
C07D 401/10 (2006.01); A61P 3/00 (2006.01); A61P 29/00 (2006.01); A61K 31/192 (2006.01); C07D 333/24 (2006.01); C07D 333/60 (2006.01); C07D 409/10 (2006.01); C07D 277/60 (2006.01); C07D 213/64 (2006.01); C07D 307/79 (2006.01); C07C 57/62 (2006.01); A61K 45/06 (2006.01); A61K 31/381 (2006.01); A61K 31/428 (2006.01); A61K 31/4418 (2006.01); C07D 339/06 (2006.01); C07D 277/66 (2006.01); C07D 333/08 (2006.01);
U.S. Cl.
CPC ...
C07D 401/10 (2013.01); A61K 31/192 (2013.01); A61K 31/381 (2013.01); A61K 31/428 (2013.01); A61K 31/4418 (2013.01); A61K 45/06 (2013.01); A61P 3/00 (2018.01); A61P 29/00 (2018.01); C07C 57/62 (2013.01); C07D 213/64 (2013.01); C07D 277/60 (2013.01); C07D 277/66 (2013.01); C07D 307/79 (2013.01); C07D 333/08 (2013.01); C07D 333/24 (2013.01); C07D 333/60 (2013.01); C07D 339/06 (2013.01); C07D 409/10 (2013.01); C07C 2601/04 (2017.05); C07C 2601/14 (2017.05); C07C 2601/16 (2017.05); C07C 2602/06 (2017.05); C07C 2602/10 (2017.05);
Abstract
The present invention relates to compound of Formula (I) containing carbon-carbon linker, a stereoisomer, a tautomer, a pharmaceutically acceptable salt, a pharmaceutically acceptable solvate, a prodrug, a polymorph, N-oxide, S-oxide, or a carboxylic acid isostere thereof; processes for their preparation; pharmaceutical compositions comprising said compounds; and their use for the treatment of the diseases or disorders mediated by GPR120 receptor.